# Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

> **NCT05504915** · — · COMPLETED · sponsor: **Osijek University Hospital** · enrollment: 31 (actual)

## Conditions studied

- Inflammatory Bowel Diseases
- Crohn Disease
- Colitis, Ulcerative

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05504915
- **Lead sponsor:** Osijek University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05504915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05504915, "Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05504915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*